Form 4: Aligos Therapeutics Director Granted Stock Options in Routine Compensation

Aligos Therapeutics, Inc. Director Bridget A Martell was granted 5,860 stock options with an exercise price of $7.63, vesting on the earlier of one year from grant or prior to the 2026 annual meeting.

Summary

• Bridget A Martell, a Director of Aligos Therapeutics, Inc. (ALGS), was granted 5,860 stock options.
• The transaction date for the grant was June 25, 2025.
• Each stock option has an exercise price of $7.63.
• The options are exercisable for 5,860 shares of Aligos Therapeutics Common Stock.
• The options will vest 100% on the earlier of the first anniversary of the grant date (June 25, 2026) or immediately prior to the Issuer's annual meeting in 2026, subject to continuous service.
• The expiration date for these stock options is June 25, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice that aligns management and director incentives with shareholder interests, indicating a routine compensation event with a generally positive implication for governance alignment.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and its shareholders.
• This is a standard form of compensation for board members, indicating routine corporate governance practices.

Future Outlook

The granted stock options are subject to a vesting schedule, with 100% vesting occurring on the earlier of the first anniversary of the grant date (June 25, 2026) or immediately prior to the Issuer's annual meeting in 2026, contingent upon continuous service.

Industry Context

The grant of stock options to a director is a common and expected practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a key component of executive and director compensation packages designed to incentivize long-term performance and align interests with shareholders.

Related Party Transactions

• Grant of 5,860 stock options to Bridget A Martell, a Director of Aligos Therapeutics, Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential alignment of the director's interests with long-term shareholder value through equity ownership, incentivizing performance that benefits the stock price.

Next Steps

• Vesting of the granted stock options based on the specified schedule (earlier of June 25, 2026, or prior to the 2026 annual meeting).

Key Dates

Keywords

Aligos Therapeutics, ALGS, Form 4, stock option, insider transaction, director compensation, equity grant, beneficial ownership